Hi Chels,
I've just been diagnosed with MMN, after an inconclusive investigation with another neuro about 1.5 yrs ago (and he advised me it was stress ...:evil
It's a very stressful time and sounds like it's been a tough road for you so far.
I'm also a youngish Mum; never been ill, so this is all rather confronting! I have found searching on the internet useful to gather more info, although I leave diagnosis & clinical advice up to my new neuro! I've downloaded lots of articles if you would like me to send them to you - just let me know your email.
Anyway, this (with my small non medical brain is what I understand so far on MMN):
- it's restricted to motor nerves, altho some minor sensory involvement has been seen in a few cases
- it typically is worse in hands / feet (distal), and of these hands are usually worse
- it's chronic - always there
- it's progressive - gradual decline or stepwise - and is asymmetrical
- some neuro reflexes may be weak or absent
- EMG shows multi focal (many areas) and persistent partial conduction block
- anti GM1 can be seen but not always, and they are not 100% sure on what the autoimmune mechanism is, but the outcome is inflammation which causes demyelination
- it usually (70-90%) of cases responds to IVIG
- if it is MMN, the sooner IVIG is started the better the likelihood of recovery of muscle strength,
- altho it won't be 100%
- there are other things that if absent assist with differential diagnosis (eg bulbar involvement
[*]untreated it will result in partial paralysis of affected areas
[*]there is no cure yet; it can go into remission
[*]if IVIG doesn't work, or efficacy fades over time, stronger immunosuppressants can be tried, but more research is needed here
[*]steroids may make it worse
[*]symptoms may include muscle weakness / tremor / twitchy muscles (fasciculations) & cramps & the pattern described above.
My neuro diagnosed on EMG, hx, physical exam and bloods, but we haven't done anti GM1 yet - he advised that was more for validation than diagnosed.
I've just started IVIG 0.4g/kg, daily induction for one week, then maintenance 1ce mthly. Only a bit tired and headaches from today (day 4). No physical change seen yet - crossing fingers!
I found getting the diagnosed and working with a great neuro to be really helpful for getting my anxiety under control.
Feel free to reach out here anytime or to me privately - I assume there's a mechanism via the board?
All the best in your journey,
from a hot and summer-is-here Australia
Jacquie
I've copied abstract from a recent o'view on MMN which I found helpful:
Multifocal Motor Neuropathy: Update on Clinical
Characteristics, Pathophysiological Concepts and
Therapeutic Options
Sven G. Meuth Christoph Kleinschnitz
Department of Neurology, University of Wuerzburg, Wuerzburg , Germany
Eur Neurol 2010;63:193–204
DOI: 10.1159/000282734
Abstract
Multifocal motor neuropathy (MMN) is an acquired immunemediated
neuropathy characterized by chronic or stepwise
progressive asymmetrical limb weakness without sensory
deficits. The upper extremities are more often affected than
the lower extremities with distal paresis dominating over
proximal paresis. Important diagnostic features are persistent
multifocal partial conduction blocks (CBs) and the presence
of high-titer anti-GM1 serum antibodies. Motor neuron
disease, other chronic dysimmune neuropathies, such as
chronic inflammatory demyelinating polyneuropathy and
the Lewis-Sumner syndrome (MADSAM neuropathy), are
important differential diagnoses. While corticosteroids and
plasma exchange are largely ineffective, high-dose intravenous
immunoglobulins are regarded as first-line treatment.
In spite of significant success in elucidating the underlying
disease mechanisms in MMN during the past few years, important
pathophysiological issues and the optimum longterm
therapy remain to be clarified. The present review summarizes
the clinical picture and current pathophysiological
concepts of MMN with a special focus on the molecular and
electrophysiological basis of CBs and highlights established
therapies as well as possible novel treatment options.
Copyright © 2010 S. Karger AG, Basel